Company Overview

Curaleaf Holdings, Inc. is a vertically integrated cannabis company operating in the U.S. cannabis and European medical cannabis industries. The company cultivates, processes, distributes, and retails cannabis products, with a focus on regulated medical and adult-use markets. Curaleaf’s core activities span plant cultivation, product manufacturing, brand development, and direct-to-consumer retail through dispensaries. Revenue is primarily driven by cannabis flower, oils, extracts, vapes, and branded consumer packaged goods sold through company-operated and wholesale channels.

Founded in 2010, Curaleaf evolved through a series of acquisitions and license wins that accelerated its expansion across multiple U.S. states. The company established itself as one of the largest multi-state operators by footprint and revenue, leveraging scale, vertical integration, and compliance capabilities in highly regulated markets. Its strategy has emphasized operational efficiency, brand consistency, and early entry into limited-license jurisdictions, which has supported market share gains in several core states.

Business Operations

Curaleaf operates through vertically integrated U.S. Cannabis Operations and International Cannabis Operations segments. In the United States, the company manages cultivation facilities, processing sites, and a large network of branded retail dispensaries under the Curaleaf name. Revenue is generated through direct retail sales and wholesale distribution of branded products, including Select, Grassroots, and Find, which are positioned across premium and value segments.

Internationally, Curaleaf focuses on medical cannabis production and distribution, primarily through Curaleaf International, which includes cultivation and processing assets in Europe and supply relationships with pharmaceutical distributors. The company controls intellectual property related to product formulations and manufacturing processes and maintains strategic partnerships with licensed operators and healthcare-focused distributors in regulated medical markets.

Strategic Position & Investments

Curaleaf’s strategic direction prioritizes disciplined growth, margin improvement, and cash flow generation within existing regulated markets. The company has historically pursued scale through acquisitions, including the acquisition of Grassroots Cannabis, which significantly expanded its U.S. footprint and retail presence. More recently, Curaleaf has emphasized operational optimization, selective capital investment, and brand-led growth rather than large-scale M&A.

The company has invested in emerging product formats such as solventless extracts, edibles, and pharmaceutical-grade medical products, as well as research related to cannabinoids and formulation consistency. Internationally, Curaleaf views European medical cannabis as a long-term growth opportunity, focusing on countries with structured reimbursement frameworks and physician-led prescribing models.

Geographic Footprint

Curaleaf is headquartered in New York, with primary operations across the United States and Europe. In the U.S., the company operates in numerous limited- and open-license states, including major markets such as Florida, New York, New Jersey, Pennsylvania, and Arizona, giving it exposure to both medical and adult-use demand.

Outside the United States, Curaleaf has a growing presence in Europe, with cultivation, manufacturing, and distribution activities in countries including Germany, United Kingdom, Portugal, and Spain. These operations position the company to supply regulated medical cannabis markets and to benefit from potential regulatory liberalization over time.

Leadership & Governance

Curaleaf was founded by Boris Jordan, who has played a central role in shaping the company’s scale-driven and compliance-focused strategy. The leadership team emphasizes disciplined execution, regulatory engagement, and long-term positioning in both U.S. and international cannabis markets. Governance is overseen by a board with experience in finance, healthcare, and regulated industries.

Key executives include:

• Boris Jordan – Executive Chairman
• Matt Darin – Chief Executive Officer
• Neil Davidson – Chief Financial Officer
• Joe Lusardi – President, U.S. Operations
• Juan Martinez – Head of Curaleaf International

The leadership team’s stated strategic vision centers on building a sustainable, globally recognized cannabis company with strong brands, regulatory credibility, and diversified geographic exposure.